# Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia

> **NCT03188458** · PHASE4 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Diphtheria-Tetanus-Acellular Pertussis

## Interventions

- **OTHER:** Blood sample

## Key facts

- **NCT ID:** NCT03188458
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-29
- **Primary completion:** 2018-10-22
- **Final completion:** 2018-10-22
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** As similar local evidence recently available, present study will not add new information; no ethical justification exists to continue study procedures.
- **Last updated:** 2019-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188458, "Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03188458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*